Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
donor-derived multi-infection specific cytotoxic T lymphocytes
- Development stage
- Unknown
- Lead developer
- University of Sydney
- Modality
- Vaccines & Immunotherapeutics, Allogeneic CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Donor-derived multi-infection specific cytotoxic T lymphocytes (CTLs) is an adoptive cellular immunotherapy developed by the University of Sydney for the prevention and treatment of opportunistic infections in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). The therapy involves the ex vivo expansion of donor-derived T cells sensitized against a broad panel of antigens from seven common post-transplant pathogens: Cytomegalovirus (CMV), Adenovirus (Adv), Epstein-Barr virus (EBV), Varicella-zoster virus (VZV), Influenza, BK polyomavirus (BKV), and the fungus Aspergillus. By providing a broad repertoire of pathogen-specific T cells, the treatment aims to bridge the period of profound immunodeficiency post-transplant. In the CYNTAX clinical protocol, these CTLs are administered in combination with early vaccination using inactivated influenza and live-attenuated VZV vaccines to promote long-term immune reconstitution and enhance the persistence of the infused T-cell memory.
- Other names
- donor-derived multi-infection specific cytotoxic T lymphocytes-University of Sydney-Cytomegalovirus infection-Adenovirus infection-Epstein-Barr virus infection-Varicella-zoster virus infection-Influenza-BK virus infection-Aspergillosis7-pathogen specific CTLsmulti-pathogen specific T-cellsdonor-derived multi-virus-specific T-cells
02
Targets
Cytomegalovirus peptide-Major Histocompatibility ComplexVaricella-zoster virus peptide-major histocompatibility complexAf-pMHC (Aspergillus fumigatus peptide antigens presented on host MHC molecules)Influenza virus peptide-Major Histocompatibility Complex (pMHC)EBNA1 (Epstein-Barr virus latency proteins)BKV antigens (BK polyomavirus antigens)HAdV (Human adenovirus)
Beyond the preview
Go deeper on donor-derived multi-infection specific cytotoxic T lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on donor-derived multi-infection specific cytotoxic T lymphocytes.